Drug updated on 11/9/2023

Dosage FormTablet (oral; 100 mg)
Drug ClassSexual Disorder Agents
Ongoing and Completed StudiesClinicalTrials.gov


  • For the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

Product Monograph / Prescribing Information

Document TitleYearSource
Addyi (flibanserin) Prescribing Information.2021Sprout Pharmaceuticals, Inc., Raleigh, NC

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines